About this trial
The purpose of this study is to assess whether Aquamin®, a multi-mineral natural product from red marine algae, can help reduce halitosis when taken for 90 days.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Must be able to give written informed consent
Willing to follow study procedures of no eating, drinking, toothbrushing, smoking or using mouth rinse 60 minutes before study visits
Have stable oral health
Self-reported halitosis
Disqualifiers
Pregnant or lactating women
Participating in any other interventional trials using an investigational drug
Diagnosed with any stomach or intestinal bleeding disorders (gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin-secreting tumors) or active gastric/duodenal ulcers - peptic ulcer disease (in last 3 months) or with severe symptoms of ulcerative colitis or Crohn's disease
Any gastrointestinal or colonic malignancy; kidney disease, including kidney "stones" or hypercalcemia
Trial design
Single group
Treatments tested in this trial
Aquamin
DrugParticipants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
Treatment groups
Trial outcomes
Primary outcomes
Halitosis Associated Life-quality Test (HALT) questionnaire (modified)
Following the intervention, participants will answer questions regarding if their bad breath has improved over the course of the study compared to the starting point. The scores will be from 0 (no issue) - 5 (worst possible issue) for each question.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.